Drug intelligence / Profile preview

LPT-205

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules

Overview

LPT-205 is an investigational "super generic" drug candidate being developed by LitePharmTech for the prevention of infections. Categorized as an improved formulation of an existing drug, LPT-205 is designed to enhance the therapeutic profile of a previously approved active pharmaceutical ingredient, potentially through improved bioavailability, safety, or administration. The project is currently in the preclinical stage of development, following the company's strategy of creating value-added medicines (also known as Incremental Modified Drugs) to address unmet clinical needs in infection control.

Beyond the preview

Go deeper on LPT-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-205.

Explore the full profile